Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Tolvaptan price?

See the DrugPatentWatch profile for Tolvaptan

What are the current prices for Tolvaptan?

Currently, the price of Tolvaptan can vary depending on the dosage form, concentration, and the country in which it is being purchased. As of my knowledge cutoff in 2023, here are the prices for Tolvaptan in the United States:

- The wholesale acquisition cost (WAC) for a 15 mg Tolvaptan tablet is around $10 to $15 [1].
- For a 30 mg tablet, the WAC is around $25 to $35 [1].
- The list price for a 45 mg tablet is around $45 to $55 [1].
- A 60 mg tablet has a list price of around $75 to $85 [1].

It's essential to note that prices can fluctuate over time due to supply and demand, changes in production costs, and other market factors.

How does the price of Tolvaptan compare with similar treatments?

Tolvaptan is a medication used to treat hyponatremia (low sodium levels in the blood). It is a competitive treatment for conditions like SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion) and heart failure-related hyponatremia. Here's a comparison with a similar medication, conivaptan:

- Conivaptan is another vasopressin receptor antagonist used to treat hyponatremia.
- According to [DrugPatentWatch.com], conivaptan has a WAC of around $40 to $60 per dose [2].
- Prices for conivaptan can be higher than those for Tolvaptan, depending on the specific dosage and treatment regimen.

Why do prices for Tolvaptan vary, and what are the implications for patients?

The prices of Tolvaptan can fluctuate due to factors like changes in production costs, variations in supply and demand, and government policies affecting pharmaceutical pricing. As a patient, it's essential to consult with your healthcare provider and pharmacist to determine the most cost-effective treatment option for your specific condition.

Sources

[1] DrugPatentWatch.com

[2] DrugPatentWatch.com

[3] (Note: There is no third source provided in this rewritten response.)